These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 34066284)

  • 1. Coagulation Signaling through PAR1 as a Therapeutic Target in Pancreatic Ductal Adenocarcinoma.
    Kothari A; Flick MJ
    Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34066284
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thrombin Signaling Promotes Pancreatic Adenocarcinoma through PAR-1-Dependent Immune Evasion.
    Yang Y; Stang A; Schweickert PG; Lanman NA; Paul EN; Monia BP; Revenko AS; Palumbo JS; Mullins ES; Elzey BD; Janssen EM; Konieczny SF; Flick MJ
    Cancer Res; 2019 Jul; 79(13):3417-3430. PubMed ID: 31048498
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thrombin-PAR1 signaling in pancreatic cancer promotes an immunosuppressive microenvironment.
    Schweickert PG; Yang Y; White EE; Cresswell GM; Elzey BD; Ratliff TL; Arumugam P; Antoniak S; Mackman N; Flick MJ; Konieczny SF
    J Thromb Haemost; 2021 Jan; 19(1):161-172. PubMed ID: 33064371
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protease-activated receptor 1 drives and maintains ductal cell fates in the premalignant pancreas and ductal adenocarcinoma.
    Tekin C; Scicluna BP; Lodestijn SC; Shi K; Bijlsma MF; Spek CA
    Mol Oncol; 2021 Nov; 15(11):3091-3108. PubMed ID: 33932087
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The therapeutic targeting of the FGFR1/Src/NF-κB signaling axis inhibits pancreatic ductal adenocarcinoma stemness and oncogenicity.
    Lai SW; Bamodu OA; Tsai WC; Chang YM; Lee WH; Yeh CT; Chao TY
    Clin Exp Metastasis; 2018 Oct; 35(7):663-677. PubMed ID: 29987671
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic trends in pancreatic ductal adenocarcinoma (PDAC).
    Chandana S; Babiker HM; Mahadevan D
    Expert Opin Investig Drugs; 2019 Feb; 28(2):161-177. PubMed ID: 30539678
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TGF-β Inhibitors in Metastatic Pancreatic Ductal Adenocarcinoma.
    Alvarez MA; Freitas JP; Mazher Hussain S; Glazer ES
    J Gastrointest Cancer; 2019 Jun; 50(2):207-213. PubMed ID: 30891677
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cotargeting of MEK and PDGFR/STAT3 Pathways to Treat Pancreatic Ductal Adenocarcinoma.
    Sahu N; Chan E; Chu F; Pham T; Koeppen H; Forrest W; Merchant M; Settleman J
    Mol Cancer Ther; 2017 Sep; 16(9):1729-1738. PubMed ID: 28619758
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MMP1/PAR1/SP/NK1R paracrine loop modulates early perineural invasion of pancreatic cancer cells.
    Huang C; Li Y; Guo Y; Zhang Z; Lian G; Chen Y; Li J; Su Y; Li J; Yang K; Chen S; Su H; Huang K; Zeng L
    Theranostics; 2018; 8(11):3074-3086. PubMed ID: 29896303
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chloroquine Potentiates the Anticancer Effect of Pterostilbene on Pancreatic Cancer by Inhibiting Autophagy and Downregulating the RAGE/STAT3 Pathway.
    Chen RJ; Lyu YJ; Chen YY; Lee YC; Pan MH; Ho YS; Wang YJ
    Molecules; 2021 Nov; 26(21):. PubMed ID: 34771150
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overcoming chemoresistance by targeting reprogrammed metabolism: the Achilles' heel of pancreatic ductal adenocarcinoma.
    Tuerhong A; Xu J; Shi S; Tan Z; Meng Q; Hua J; Liu J; Zhang B; Wang W; Yu X; Liang C
    Cell Mol Life Sci; 2021 Jul; 78(14):5505-5526. PubMed ID: 34131808
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody-based targeting of alternatively spliced tissue factor: a new approach to impede the primary growth and spread of pancreatic ductal adenocarcinoma.
    Unruh D; Ünlü B; Lewis CS; Qi X; Chu Z; Sturm R; Keil R; Ahmad SA; Sovershaev T; Adam M; Van Dreden P; Woodhams BJ; Ramchandani D; Weber GF; Rak JW; Wolberg AS; Mackman N; Versteeg HH; Bogdanov VY
    Oncotarget; 2016 May; 7(18):25264-75. PubMed ID: 26967388
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel agents for pancreatic ductal adenocarcinoma: emerging therapeutics and future directions.
    Zhang Y; Yang C; Cheng H; Fan Z; Huang Q; Lu Y; Fan K; Luo G; Jin K; Wang Z; Liu C; Yu X
    J Hematol Oncol; 2018 Jan; 11(1):14. PubMed ID: 29386069
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting the tumor microenvironment for pancreatic ductal adenocarcinoma therapy.
    Zhang YF; Jiang SH; Hu LP; Huang PQ; Wang X; Li J; Zhang XL; Nie HZ; Zhang ZG
    Chin Clin Oncol; 2019 Apr; 8(2):18. PubMed ID: 31070038
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-tumor effects of a 'human & mouse cross-reactive' anti-ADAM17 antibody in a pancreatic cancer model in vivo.
    Ye J; Yuen SM; Murphy G; Xie R; Kwok HF
    Eur J Pharm Sci; 2017 Dec; 110():62-69. PubMed ID: 28554668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of cell death in pancreatic ductal adenocarcinoma by indirubin 3'-oxime and 5-methoxyindirubin 3'-oxime in vitro and in vivo.
    Sano M; Ichimaru Y; Kurita M; Hayashi E; Homma T; Saito H; Masuda S; Nemoto N; Hemmi A; Suzuki T; Miyairi S; Hao H
    Cancer Lett; 2017 Jul; 397():72-82. PubMed ID: 28347789
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cancer-associated fibroblasts in pancreatic adenocarcinoma.
    Pan B; Liao Q; Niu Z; Zhou L; Zhao Y
    Future Oncol; 2015 Sep; 11(18):2603-10. PubMed ID: 26284509
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A nicotine-induced positive feedback loop between HIF1A and YAP1 contributes to epithelial-to-mesenchymal transition in pancreatic ductal adenocarcinoma.
    Ben Q; An W; Sun Y; Qian A; Liu J; Zou D; Yuan Y
    J Exp Clin Cancer Res; 2020 Sep; 39(1):181. PubMed ID: 32894161
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting PIN1 exerts potent antitumor activity in pancreatic ductal carcinoma via inhibiting tumor metastasis.
    Chen L; Xu X; Wen X; Xu S; Wang L; Lu W; Jiang M; Huang J; Yang D; Wang J; Zheng M; Zhou XZ; Lu KP; Liu H
    Cancer Sci; 2019 Aug; 110(8):2442-2455. PubMed ID: 31148345
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IL6 Receptor Blockade Enhances Chemotherapy Efficacy in Pancreatic Ductal Adenocarcinoma.
    Long KB; Tooker G; Tooker E; Luque SL; Lee JW; Pan X; Beatty GL
    Mol Cancer Ther; 2017 Sep; 16(9):1898-1908. PubMed ID: 28611107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.